health

This paper presents the complete, peer-reviewed results of the open-label Phase 1/2 portion of SUNRISE-PD (NCT03720418) — the first human trial of OXB-102/AXO-Lenti-PD, a lentiviral gene therapy for Parkinson's disease. A lentiviral vector is a modified, harmless virus used as a delivery vehicle. The therapy carries three genes — tyrosine hydroxylase (TH), GTP cyclohydrolase 1 (GCH1), and aromatic L-amino acid decarboxylase (AADC) — the enzymes that together allow a cell to manufacture dopamine from scratch. Surgeons infused the vector bilaterally into the putamen (the brain region most depleted of dopamine in PD). The idea: gene-modified striatal cells produce a steady, continuous trickle of dopamine, potentially smoothing out the on-off fluctuations driven by the rise and fall of oral levodopa. Six participants with moderate-to-severe PD received the therapy in two dose cohorts (two patients at a low dose; four at an intermediate dose). No serious adverse events related to the gene therapy were reported. Motor scores during the medication-off state (UPDRS-III off, the standard scale for rating movement problems when levodopa has worn off) improved by roughly 40% from baseline in both cohorts, and daily oral levodopa requirements fell by around 20%. The program was commercially terminated in 2022 — before the planned sham-surgery-controlled phase — when the sponsor relinquished its licence. This 2025 Movement Disorders paper is the first full, peer-reviewed record of those findings, previously available only in press releases and conference abstracts.

How to calibrate this: the study is very early and very small — six patients, no control group. In open-label neurosurgical trials a strong placebo effect lasting six to twelve months is well documented, so improvements cannot be confidently attributed to the drug. The programme is terminated and there is no current plan to continue it. What this paper does usefully is put the safety and biomarker data on permanent scientific record, inform the design of successor programmes, and confirm that a single-administration lentiviral dopamine gene therapy can be tolerated without serious drug-related harms at the doses tested.

For someone living with Parkinson's: OXB-102/AXO-Lenti-PD is not available and has no active development path. The broader field of dopamine gene therapy is alive — other approaches using different viral vectors and genes are in active or planned trials — but none are close to regulatory approval. If you are interested in gene therapy trials, ask your neurologist about currently enrolling studies such as REGENERATE-PD (AAV2-GDNF). The concept explored here — one surgical procedure replacing years of tablets — remains scientifically credible and motivates continued research.